Results 31 to 40 of about 38,595 (290)

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysisResearch in context

EClinicalMedicine, 2023
Summary: Background: Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA plus sodium glucose cotransporter-2 inhibitors [SGLT-2i] combinations ...
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F.M. Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino   +10 more
doaj   +1 more source

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea

, 2023
Bile acid diarrhea (BAD) is a socially debilitating disease. Typical symptoms include loose stools, urgency, and high stool frequency. Recently, we reported the superior efficacy of the glucagon like-peptide 1 receptor agonist (GLP-1RA) liraglutide ...
Knudsen, Elisabeth, Knop, Filip Krag, Kårhus, Martin Lund   +2 more
core   +1 more source

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study

, 2020
BackgroundWe investigated changes in clinical characteristics of SGLT2i and GLP-1RA real-world initiators in Denmark before/after landmark cardiovascular outcome trials.MethodsWe compared first-time SGLT2i (25,070) and GLP-1RA (14,671) initiators to ...
Reimar W. Thomsen (8532312), Henrik T Sørensen, Anastasia Ustyugova (3588770), Larisa Nurkanovic, Maria Lajer (135188), Anastasia Ustyugova, Lisbeth M. Baggesen (8532306), Henrik T. Sørensen (8445630), Jakob S. Knudsen (8532303), Lisbeth M Baggesen, Reimar W Thomsen, Jakob S Knudsen, Larisa Nurkanovic (8532309), Maria Lajer   +13 more
core   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background We investigated the effects of insulin, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i), and their combination on vascular and cardiac function of patients with type 2 diabetes mellitus.
Ignatios Ikonomidis, George Pavlidis, John Thymis, Dionysia Birba, Aimilianos Kalogeris, Foteini Kousathana, Aikaterini Kountouri, Konstantinos Balampanis, John Parissis, Ioanna Andreadou, Konstantinos Katogiannis, George Dimitriadis, Aristotelis Bamias, Efstathios Iliodromitis, Vaia Lambadiari   +14 more
doaj   +1 more source

Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong

Cardiovascular Diabetology, 2023
Background There are limited data on head-to-head comparative risk of stroke between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).
David Tak Wai Lui, Eric Ho Man Tang, Tingting Wu, Ivan Chi Ho Au, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan, Carlos King Ho Wong   +7 more
doaj   +1 more source

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway

, 2023
Jie Xiang,1 Liyan Qin,2 Jinling Zhong,3 Ning Xia,2 Yuzhen Liang3 1Department of Clinical Nutrition, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China; 2Department of Geriatric Endocrinology, The First ...
Qin L, Liang Y, Xia N, Xiang J, Zhong J
core  

Understanding the place for GLP-1RA therapy:Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection

, 2021
Since the first glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA) was approved in 2005 (exenatide twice daily) for type 2 diabetes (T2D), the class has developed with newer compounds having more pronounced effects on glycaemic control and body ...
Andreasen, Christine Rode, Andreas Andersen, Filip Krag Knop, Vilsbøll, Tina, Christine Rode Andreasen, Andersen, Andreas, Knop, Filip Krag, Tina Vilsbøll   +7 more
core   +1 more source

Participants baseline characteristics (GLP-1RA cohort, n = 257).

, 2016
Participants baseline characteristics (GLP-1RA cohort, n = 257).
Mike Lonergan (490181), Beverley M. Shields (146725), Ewan R. Pearson (157520), Andrew T. Hattersley (146736), Angus G. Jones (650402), William E. Henley (311559)   +5 more
core   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon‐Like Peptide 1 Receptor Agonists

OTO Open
Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) have shown remarkable results in glycemic control for patients with type 2 diabetes (T2DM). While no association has been made, there is a concern for thyroid cancer (TC) from GLP‐1RA.
Bao Y. Sciscent, Hanel W. Eberly, F. Jeffrey Lorenz, David Goldrich, Neerav Goyal, David Goldenberg   +5 more
doaj   +1 more source